Our Podcast
MDS Patient & Family Report
This new initiative of the MDS Foundation is devoted to patients, family members, and other non-professional interested people. In each episode, experts in the field will discuss novel information on MDS, such as new diagnostic techniques, new therapies etc. They will also answer frequently asked questions, which are relevant to many people.
![MDS Highlights of the 2024 European Hematology Association Congress [MDS Patient & Family Report]](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_160/images.spreaker.com/original/3e2ee2cf18d85ac46782f6c6a5047d8f.jpg)
October 28, 2024
4. MDS Highlights of the 2024 European Hematology Association Congress [MDS Patient & Family Report]
Dr. Rena Buckstein and Dr. Moshe Mittelman join Dr. Nikolaos Papadantonakis to discuss key MDS abstracts presented in the 2024 European Hematology Association Congress. Topics covered include anemia and the role of ivosidenib in higher risk MDS.
July 29, 2024
3. Introduction to cytogenetics and mutational testing in MDS [MDS Patient & Family Report]
Dr. Nikolaos Papadantonakis discusses cytogenetics and mutational testing in MDS with Dr. Hetty Carraway and Dr. Moshe Mittelman and how they utilize this information in the clinical setting.
![Overview of MDS treatments [MDS Patient & Family Report]](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_160/images.spreaker.com/original/6fb86eb9669a4d2de76fbe628d3c3231.jpg)
April 30, 2024
2. Overview of MDS treatments [MDS Patient & Family Report]
In this episode, Dr. Papadantonakis from Winship Cancer Institute of Emory University, Atlanta, US, and Dr. Mittelman, chairman of the MDS Foundation scientific board, discuss the range of treatment options for patients with MDS.
March 27, 2024
1. New drugs for anemia of lower-risk MDS [MDS Patient & Family Report]
MDS experts Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss new trials presented in the last meeting of the American Society of Hematology (ASH) 2023. They focus on luspatercept, imetelstat and roxodustat.
